MESOBLAST LTD
MESONext catalyst
Rexlemestrocel-L + HA mixture
Degenerative Disc Disease
Get an email about MESO's next catalysts
Track MESOBLAST (MESO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
Rexlemestrocel-L + HA mixture Phase 3 Est. Readout (HyaluronicAcid)
Primary completion for Rexlemestrocel-L + HA mixture trial (NCT06325566) in Degenerative Disc Disease
SourceMarket Overview
Stock performance and key metrics
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
WebsiteRexlemestrocel-L
Degenerative Disc Disease
adult human mesenchymal stem cells
Crohn's Disease
Prochymal®
Graft Versus Host Disease
remestemcel-L
Grade B aGVHD
PROCHYMAL adult human mesenchymal stem cells
Crohn's Disease
one MPC expanded cord unit and one unexpanded cord unit
Acute Myelogenous Leukemia
Allogeneic Mesenchymal Precursor Cells (MPCs)
Chronic Heart Failure
Rexlemestrocel-L + HA mixture
Degenerative Disc Disease
Allogeneic Mesenchymal Precursor Cells
Rheumatoid Arthritis
Mesenchymal Precursor Cells (MPC) 12.5 M
Acute Myocardial Infarction
Lumbar Interbody Fusion with NeoFuse
Degenerative Disc Disease
Prochymal™ adult human mesenchymal stem cells
Crohn's Disease
Prochymal®- 8 Million cells/kg
Graft Vs Host Disease
Prochymal® - 2 Million cells/kg
Graft Vs Host Disease
Hyaluronan
Recovery Following Partial Medial Meniscectomy
Prochymal
Graft Versus Host Disease
Lumbar Interbody Fusion with Autograft
Degenerative Disc Disease
Prochymal™
Pulmonary Disease, Chronic Obstructive
Single Dose MPCs Injection
Degenerative Disc Disease
Mesenchymal Precursor Cells (MPC) 25 M
Acute Myocardial Infarction
Mesenchymal Stem Cells
Recovery Following Partial Medial Meniscectomy
MSB-CAR001 Combined With Hyaluronan
Anterior Cruciate Ligament Injury
Chondrogen
Recovery Following Partial Medial Meniscectomy
Mesenchymal Precursor Cells (MPCs)
Diabetic Nephropathy
NeoFuse
Cervical Degenerative Disc Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rexlemestrocel-L | Phase 3 | Degenerative Disc Disease | - | - |
adult human mesenchymal stem cells | Phase 3 | Crohn's Disease | - | - |
Prochymal® | Phase 3 | Graft Versus Host Disease | - | - |
remestemcel-L | Phase 3 | Grade B aGVHD | - | - |
PROCHYMAL adult human mesenchymal stem cells | Phase 3 | Crohn's Disease | - | - |
one MPC expanded cord unit and one unexpanded cord unit | Phase 3 | Acute Myelogenous Leukemia | - | - |
Allogeneic Mesenchymal Precursor Cells (MPCs) | Phase 3 | Chronic Heart Failure | - | - |
Rexlemestrocel-L + HA mixture | Phase 3 | Degenerative Disc Disease | - | - |
Allogeneic Mesenchymal Precursor Cells | Phase 2 | Rheumatoid Arthritis | - | - |
Mesenchymal Precursor Cells (MPC) 12.5 M | Phase 2 | Acute Myocardial Infarction | - | - |
Lumbar Interbody Fusion with NeoFuse | Phase 2 | Degenerative Disc Disease | - | - |
Prochymal™ adult human mesenchymal stem cells | Phase 2 | Crohn's Disease | - | - |
Prochymal®- 8 Million cells/kg | Phase 2 | Graft Vs Host Disease | - | - |
Prochymal® - 2 Million cells/kg | Phase 2 | Graft Vs Host Disease | - | - |
Hyaluronan | Phase 2 | Recovery Following Partial Medial Meniscectomy | - | - |
Prochymal | Phase 2 | Graft Versus Host Disease | - | - |
Lumbar Interbody Fusion with Autograft | Phase 2 | Degenerative Disc Disease | - | - |
Prochymal™ | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Single Dose MPCs Injection | Phase 2 | Degenerative Disc Disease | - | - |
Mesenchymal Precursor Cells (MPC) 25 M | Phase 2 | Acute Myocardial Infarction | - | - |
Mesenchymal Stem Cells | Phase 2 | Recovery Following Partial Medial Meniscectomy | - | - |
MSB-CAR001 Combined With Hyaluronan | Phase 2 | Anterior Cruciate Ligament Injury | - | - |
Chondrogen | Phase 2 | Recovery Following Partial Medial Meniscectomy | - | - |
Mesenchymal Precursor Cells (MPCs) | Phase 2 | Diabetic Nephropathy | - | - |
NeoFuse | Phase 2 | Cervical Degenerative Disc Disease | - | - |
Frequently asked questions
What is in MESOBLAST LTD's drug pipeline?→
CatalystAlert tracks 25 drug candidates in MESOBLAST LTD's (MESO) pipeline across Phase 3, Phase 2. Its lead program is Rexlemestrocel-L + HA mixture (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MESOBLAST LTD's next FDA catalyst?→
MESOBLAST LTD's (MESO) next tracked catalyst is a Phase 3 readout expected July 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MESO biotech catalysts?→
Add MESO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MESOBLAST LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
